M&A Strategy and Preparations for Pharmacies in Light of the 2026 Medical Fee Revision—3 Key Points to Know During a Major Transformation in Pharmacy Operations – Yamada & Partners Tax Corporation

News Summary

With the medical fee revision for fiscal year 2026 on the horizon, the dispensing pharmacy industry is facing a significant turning point. Yamada & Partners Tax Corporation highlights the importance of M&A strategies and preparations in this context. They explain that mid- to long-term strategies that consider the revision cycle, the economies of scale through group participation (maintaining facility standards, distributing equipment investment costs), and the utilization of tax schemes including transitions to specific medical corporations and social medical corporations are key to pharmacy management.

M&A Medical Editorial Department’s Perspective

The medical fee revision for fiscal year 2026 will likely serve as a catalyst for dispensing pharmacies to more strongly consider M&A as an option in their management strategies. In particular, the “economies of scale” such as maintaining facility standards and distributing equipment investment costs, which will be discussed later, can make M&A through group formation a realistic solution for small and medium-sized pharmacies that may find independent operation increasingly difficult. Furthermore, utilizing tax schemes with a view to transitioning to specific medical corporations or social medical corporations can go beyond simple business succession, becoming an advanced M&A strategy to balance contributions to regional healthcare with operational efficiency. This tax corporation’s proposal can be seen not just as a “survival strategy” but as suggesting a concrete path to seize change as an opportunity and build a more robust management foundation.

Points Raised by This News

• The 2026 medical fee revision will have a significant impact on M&A strategies for dispensing pharmacies.
• To maintain facility standards and distribute equipment investment costs, “economies of scale” through group formation are emphasized.
• Utilizing tax schemes with a view to transitioning to specific medical corporations and social medical corporations balances operational efficiency and regional contribution.
• Developing mid- to long-term management and succession strategies that consider the revision cycle is essential.

Practical Questions Arising from This News

• What specific changes in the 2026 medical fee revision are predicted to affect the revenue of dispensing pharmacies?
• What specific benefits are encompassed by the “economies of scale” through group formation?
• Under what conditions is it possible to transition to specific medical corporations or social medical corporations, and what tax incentives can be expected?

If You Feel “Should I Consult Too?”

Business owners who are concerned about responding to the fiscal year 2026 medical fee revision and wish to begin concrete planning regarding their pharmacy’s future management strategy and succession are encouraged to consult with experts, including exploring M&A possibilities, prompted by this news. In particular, those interested in specific strategies such as economies of scale and tax schemes will find that early consultation is key to achieving business succession or group formation under more favorable terms.

M&A Medical (CentralMedience Inc.) supports the business succession of medical corporations, hospitals, and clinics on a full success fee basis as an M&A support institution certified by the Small and Medium Enterprise Agency. Consultations are kept strictly confidential. Free consultation here